RSII "Product samples shipped to dozens of recipients on June 13, 2017 and the feedback continues to be overwhelmingly positive," states CEO Robert Weber. "We can't help be excited for the future for Rising BioSciences and its shareholders. With a finalized merger and products undergoing testing for FDA approval, we are on the cusp of delivering effective, non-opiate medication nationwide; using alternative medicine, including both Cannabis and non-Cannabis based solutions.